Aimmune Therapeutics Company Profile (NASDAQ:AIMT)

About Aimmune Therapeutics

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company's Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. Its lead product, AR101, which has completed a Phase II study, is designed to treat peanut allergy. The Company's AR101 is a mixture of naturally occurring proteins and pharmaceutical-grade ingredients. Its CODIT system aims to improve upon oral immunotherapy (OIT) by precisely controlling the amount of food protein administered and establishing very gradual treatment regimens that begin with low doses of protein.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: AIMT
CUSIP:

Key Metrics:

Previous Close: $16.57
50 Day Moving Average: $14.84
200 Day Moving Average: $13.61
52-Week Range: $9.77 - $26.50
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -7.47
P/E Growth: 0.23
Market Cap: $672.26M
Outstanding Shares: 42,254,000

Profitability:

Return on Equity: -1,239.53%
Return on Assets: -28.59%

Debt:

Current Ratio: 29.58%
Quick Ratio: 29.58%

Additional Links:

Companies Related to Aimmune Therapeutics:

Consensus Ratings for Aimmune Therapeutics (NASDAQ:AIMT) (?)

Ratings Breakdown:	5 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$36.25 (127.84% upside)

Analysts' Ratings History for Aimmune Therapeutics (NASDAQ:AIMT)

Show:

Date	Firm	Action	Rating	Price Target
9/26/2016	JMP Securities	Initiated Coverage	Outperform	$30.00
9/23/2016	Piper Jaffray Cos.	Reiterated Rating	Overweight	$38.00
9/21/2016	Wedbush	Reiterated Rating	Outperform	$42.00
8/19/2016	Credit Suisse Group AG	Reiterated Rating	Buy	$35.00
5/16/2016	Bank of America Corp.	Reiterated Rating	Buy

(Data available from 9/27/2014 forward)

Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/2/2016
8/10/2016	Q216	($0.42)	($0.43)	View	N/A
5/16/2016	Q116	($0.40)	($0.37)	View	N/A
3/3/2016	Q415	($0.35)	($0.39)	View	Listen

(Data available from 1/1/2011 forward)

Earnings Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Current Year EPS Consensus Estimate: $-1.7 EPS
Next Year EPS Consensus Estimate: $-2.13 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	($0.28)	($0.28)	($0.28)
Q2 2016	1	($0.39)	($0.39)	($0.39)
Q3 2016	1	($0.44)	($0.44)	($0.44)
Q4 2016	1	($0.46)	($0.46)	($0.46)
Q1 2017	1	($0.48)	($0.48)	($0.48)
Q2 2017	1	($0.50)	($0.50)	($0.50)
Q3 2017	1	($0.52)	($0.52)	($0.52)
Q4 2017	1	($0.54)	($0.54)	($0.54)

(Data provided by Zacks Investment Research)

Dividend History for Aimmune Therapeutics (NASDAQ:AIMT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Aimmune Therapeutics (NASDAQ:AIMT)

Insider Ownership Percentage: 24.56%
Institutional Ownership Percentage: 68.87%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/8/2016	Mary M Rozenman	Insider	Sell	30,000	$16.80	$504,000.00
5/31/2016	Foresite Capital Fund Ii, L.P.	Major Shareholder	Sell	240,000	$15.23	$3,655,200.00
3/29/2016	Longitude Capital Partners Ii,	Major Shareholder	Buy	78,504	$13.87	$1,088,850.48

(Data available from 1/1/2013 forward)

Latest Headlines for Aimmune Therapeutics (NASDAQ:AIMT)

Date	Headline
	Coverage initiated on Aimmune Therapeutics by JMP Securities (NASDAQ:AIMT) finance.yahoo.com - September 26 at 3:24 PM
	Aimmune Therapeutics Inc. (NASDAQ: AIMT) Rating Reiterated at Wedbush - BNB Daily (blog) (NASDAQ:AIMT) www.baseball-news-blog.com - September 22 at 9:18 AM
	Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company ... (NASDAQ:AIMT) www.businesswire.com - September 21 at 4:20 PM
	Aimmune Therapeutics (AIMT) Completes Target Enrollment in AR101 Phase 3 PALISADE Trial (NASDAQ:AIMT) www.streetinsider.com - September 21 at 4:20 PM
	Aimmune Therapeutics Inc Conference Call to Discuss the AR101 Clinical Program Updates scheduled for 5:00 pm ET today (NASDAQ:AIMT) biz.yahoo.com - September 21 at 4:20 PM
	Aimmune Therapeutics (AIMT) Completes Target Enrollment in AR101 Phase 3 PALISADE Trial - StreetInsider.com (NASDAQ:AIMT) www.streetinsider.com - September 21 at 10:07 AM
	AIMMUNE THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib (NASDAQ:AIMT) biz.yahoo.com - September 21 at 10:07 AM
	Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S. (NASDAQ:AIMT) www.publicnow.com - September 21 at 10:07 AM
	Analyst Consensus Estimates & Projections are in For Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) - Frisco Fastball (NASDAQ:AIMT) friscofastball.com - September 20 at 3:23 PM
	Sell-side is Weighing in on Aimmune Therapeutics Inc (NASDAQ:AIMT) Earnings - Frisco Fastball (NASDAQ:AIMT) friscofastball.com - September 19 at 8:09 AM
	Aimmune Therapeutics Inc (AIMT) Stock Price Down 6.3% Following Insider Selling - DailyQuint (NASDAQ:AIMT) dailyquint.com - September 19 at 8:09 AM
	What are Research Firms Saying About Aimmune Therapeutics Inc (NASDAQ:AIMT)? - Frisco Fastball (NASDAQ:AIMT) friscofastball.com - September 17 at 3:23 PM
	Earnings Analysis & Update for Aimmune Therapeutics Inc (NASDAQ:AIMT)? - Frisco Fastball (NASDAQ:AIMT) friscofastball.com - September 17 at 8:09 AM
	Stock Update on Earnings & Estimates for Aimmune Therapeutics Inc (NASDAQ:AIMT) - Frisco Fastball (NASDAQ:AIMT) friscofastball.com - September 15 at 3:21 PM
	Analysts Take: Aimmune Therapeutics Inc (NASDAQ:AIMT) Projected Earnings & Price Targets - Frisco Fastball (NASDAQ:AIMT) friscofastball.com - September 14 at 3:23 PM
	Aimmune Therapeutics, Inc. :AIMT-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:AIMT) www.capitalcube.com - September 14 at 9:13 AM
	Aimmune Therapeutics Inc. (NASDAQ: AIMT) Stock Upgraded at ... - BNB Daily (blog) (NASDAQ:AIMT) www.baseball-news-blog.com - August 29 at 8:08 AM
	Investment Analysts' Updated EPS Estimates for August, 26th (AIMT,... (NASDAQ:AIMT) www.topix.com - August 27 at 8:10 AM
	Aimmune Therapeutics Inc. (NASDAQ: AIMT) Stock Rating Reiterated at Wedbush - BNB Daily (blog) (NASDAQ:AIMT) www.baseball-news-blog.com - August 25 at 3:23 PM
	Aimmune Therapeutics (AIMT): Expecting Success In Palisades Trial - Piper Jaffray - StreetInsider.com (NASDAQ:AIMT) www.streetinsider.com - August 23 at 8:55 AM
	Newly released market study: Aimmune Therapeutics, Inc. (AIMT) - Financial and Strategic SWOT Analysis Review (NASDAQ:AIMT) www.live-pr.com - August 22 at 8:11 AM
	Aimmune Therapeutics Inc Call to Discuss the Publication of the DEVIL study data and potential implications for development of AR101 scheduled for 4:30 pm ET today (NASDAQ:AIMT) biz.yahoo.com - August 22 at 8:11 AM
	AIMMUNE THERAPEUTICS, INC. Financials (NASDAQ:AIMT) finance.yahoo.com - August 20 at 3:25 PM
	News review of 2 biotech stocks: Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Raptor Pharmaceuticals Corp ... - The Voice Registrar (NASDAQ:AIMT) voiceregistrar.com - August 20 at 8:22 AM
	Active News in Reviews- OncoMed Pharmaceuticals (OMED), Aimmune Therapeutics (AIMT), Cardinal Financial (CFNL) - Seneca Globe (NASDAQ:AIMT) www.senecaglobe.com - August 19 at 11:49 AM
	8:02 am Aimmune Therapeutics will host call to discuss the results of an independent academic clinical trial demonstrating the ability of low-dose oral immunotherapy to induce unresponsiveness in peanut-allergic children (NASDAQ:AIMT) finance.yahoo.com - August 18 at 11:48 AM
	Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children (NASDAQ:AIMT) www.publicnow.com - August 18 at 11:48 AM
	Aimmune Therapeutics Inc (NASDAQ:AIMT) Is Bringing A 100 Year Old Treatment Into The 21st Century - Market Exclusive (NASDAQ:AIMT) marketexclusive.com - August 16 at 3:25 PM
	Aimmune Therapeutics Inc (AIMT) Is Bringing A 100 Year Old Treatment Into The 21st Century (NASDAQ:AIMT) www.insidermonkey.com - August 16 at 3:25 PM
	Aimmune Therapeutics Inc (NASDAQ:AIMT) Is Bringing A 100 Year Old Treatment Into The 21st Century (NASDAQ:AIMT) marketexclusive.com - August 16 at 11:59 AM
	Worth Watching Stocks: Aimmune Therapeutics, Inc. (NASDAQ:AIMT), Pernix Therapeutics Holdings, Inc. (NASDAQ ... - KC Register (NASDAQ:AIMT) www.kcregister.com - August 15 at 10:39 AM
	Aimmune Announces Second Quarter 2016 Financial Results (NASDAQ:AIMT) www.biospace.com - August 11 at 9:16 PM
	Aimmune Therapeutics reports 2Q loss (NASDAQ:AIMT) sg.finance.yahoo.com - August 10 at 9:50 PM
	Aimmune Therapeutics Announces Second Quarter 2016 Financial Results (NASDAQ:AIMT) www.publicnow.com - August 10 at 9:50 PM
	Aimmune Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:AIMT) finance.yahoo.com - August 9 at 12:09 PM
	Aimmune Therapeutics Inc Can't Burn Your Long Portfolio. Has Another Strong Session - Consumer Eagle (NASDAQ:AIMT) www.consumereagle.com - July 22 at 8:24 PM
	Aimmune Therapeutics Inc Gaps Up; Strong Momentum for Buyers - Consumer Eagle (NASDAQ:AIMT) www.consumereagle.com - July 22 at 3:22 PM
	Stock Moving Lower for the Month; Investor Update on Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily (NASDAQ:AIMT) www.engelwooddaily.com - July 21 at 3:22 PM
	Aimmune Therapeutics Inc's Stock Is Buy After Today's Huge Increase - Consumer Eagle (NASDAQ:AIMT) www.consumereagle.com - July 21 at 3:22 PM
	Aimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorted Shares Increased 23.82% After Market Selling - Consumer Eagle (NASDAQ:AIMT) www.consumereagle.com - July 19 at 3:24 PM
	Increased Volatility Noted on Shares of: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily (NASDAQ:AIMT) www.engelwooddaily.com - July 16 at 3:22 PM
	Increased Volatility Noted on Shares of: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily (NASDAQ:AIMT) www.engelwooddaily.com - July 16 at 3:22 PM
	How Many Aimmune Therapeutics Inc (NASDAQ:AIMT)'s Analysts Are Bullish? - Consumer Eagle (NASDAQ:AIMT) www.consumereagle.com - July 16 at 3:22 PM
	How Many Aimmune Therapeutics Inc (NASDAQ:AIMT)'s Analysts Are Bullish? - Consumer Eagle (NASDAQ:AIMT) www.consumereagle.com - July 16 at 3:22 PM
	Aimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorted Shares Increased 2.16% After Market Selling - Consumer Eagle (NASDAQ:AIMT) www.consumereagle.com - July 16 at 3:22 PM
	Aimmune Therapeutics Incorporated (NASDAQ:AIMT) Shorted Shares Increased 2.16% After Market Selling - Consumer Eagle (NASDAQ:AIMT) www.consumereagle.com - July 16 at 3:22 PM
	Shares Losing Ground for the Month; Investor Alert on Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily (NASDAQ:AIMT) www.engelwooddaily.com - July 14 at 12:18 PM
	Eye on Stock Volatility for: Aimmune Therapeutics, Inc. (NASDAQ:AIMT) - Engelwood Daily (NASDAQ:AIMT) www.engelwooddaily.com - July 14 at 12:18 PM
	Aimmune Therapeutics Incorporated (NASDAQ:AIMT) Sellers Increased By 2.16% Their Shorts - Consumer Eagle (NASDAQ:AIMT) www.consumereagle.com - July 13 at 11:28 AM
	Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:AIMT) www.fiscalstandard.com - July 11 at 8:11 AM